2.2. mRNA Sequencing Indicated That Resmetirom Might Improve NAFLD/NASH by Influencing the Activation of Toll-like Receptor and Jak-STAT3 Signaling Pathways. The gene discussed is STAT3; the disease is metabolic dysfunction-associated steatohepatitis.